Narasimhan
Biotech

Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts

Novartis is “continuing to evaluate” the in vivo CAR-T space, although the pharma’s CEO told Fierce Biotech that no deals are currently in the works.
James Waldron Apr 28, 2026 3:21am
obesity overweight weight loss weigh

Boehringer links dual agonist to 16.6% weight loss in phase 3

Apr 28, 2026 4:00am
Garbage truck picking up trash on suburban street

Janux axes solid tumor T-cell engager after poor ph. 1 showing

Apr 28, 2026 4:15am
Photo of five sailboats setting out in the same direction over dark blue water

Seaport, Hemab chart courses for $180M IPOs this week

Apr 27, 2026 12:29pm
Goal disorientation and lack of vision

Compass Therapeutics' stock heads south after bispecific OS miss

Apr 27, 2026 10:55am
Assorted cleaning supplies sitting on a wooden table

Astellas thins early pipeline, swaps out struggling gene therapy

Apr 27, 2026 10:38am
More News
Fierce Pharma

Ligand lays out $739M for royalty aggregator compatriot Xoma

Apr 27, 2026 10:19am

Oruka’s psoriasis data hailed as ‘outright win over Skyrizi’

Apr 27, 2026 9:51am

Intellia races in vivo CRISPR therapy to FDA after phase 3 win

Apr 27, 2026 9:24am

Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax

Apr 27, 2026 8:25am